Literature DB >> 27586145

Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer.

Juliana Carron1, Angelo Borsarelli Carvalho Brito1, Ana Carolina Mourão Torelli1, Cristiane Oliveira1, Sophie Françoise Mauricette Derchain2, Carmen Silvia Passos Lima1, Gustavo Jacob Lourenço3.   

Abstract

This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients. DNA from 84 EOC patients diagnosed at the University of Campinas Academic Hospital from January 1995 and July 2007 was analyzed by polymerase chain reaction and restriction fragment length polymorphism assays. The prognostic impact of genotypes of polymorphisms on progression-free survival and overall survival (OS) of EOC patients was examined using the Kaplan-Meier probability estimates and univariate and multivariate Cox proportional hazard ratio (HR) regression analyses. The significant results of Cox analyses were validated using a bootstrap resampling study (1000 replications). At 60 months of follow-up, lower OS was seen in patients with GSTT1 null genotype (50.0 vs. 76.7 %, P = 0.02) compared with the other genotype (Kaplan-Meier estimate). This outcome remained the same in univariate Cox analysis (HR 2.22, P = 0.02). After multivariate Cox analysis, patients with GSTT1 null (HR 2.11, P = 0.04, P bootstrap = 0.04) and NQO2 AA (HR 2.13, P = 0.03, P bootstrap = 0.04) genotypes were under greater risks of progressing to death when compared with those with others genotypes. Our data suggest, for the first time, that inherited abnormalities in xenobiotic detoxification pathway related to GSTT1 and NQO2 c.-102A>C polymorphisms act as independent prognostic factors for OS of EOC patients.

Entities:  

Keywords:  Epithelial ovarian cancer; GSTT1; NQO2; Prognosis; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27586145     DOI: 10.1007/s12032-016-0819-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Authors:  Jaime Prat
Journal:  Int J Gynaecol Obstet       Date:  2013-10-22       Impact factor: 3.561

2.  Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.

Authors:  Elaine Cristina Morari; Andre Bacellar Costa Lima; Natassia Elena Bufalo; Janaina Luisa Leite; Fabiana Granja; Laura Sterian Ward
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

3.  Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma.

Authors:  Stefan Hohaus; Annalisa Di Ruscio; Annalaura Di Febo; Giuseppina Massini; Francesco D'Alo'; Francesco Guidi; Giovanna Mansueto; Maria Teresa Voso; Giuseppe Leone
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

4.  Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.

Authors:  A Beeghly; D Katsaros; H Chen; S Fracchioli; Y Zhang; M Massobrio; H Risch; B Jones; H Yu
Journal:  Gynecol Oncol       Date:  2005-09-29       Impact factor: 5.482

Review 5.  Glutathione transferases.

Authors:  John D Hayes; Jack U Flanagan; Ian R Jowsey
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

6.  The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics.

Authors:  Kira Philipsen Prahm; Mona Aarenstrup Karlsen; Estrid Høgdall; Nikolai Madrid Scheller; Lene Lundvall; Lotte Nedergaard; Ib Jarle Christensen; Claus Høgdall
Journal:  Gynecol Oncol       Date:  2014-12-27       Impact factor: 5.482

7.  The role of glutathione-S-transferase polymorphisms in ovarian cancer survival.

Authors:  Christina M Nagle; Georgia Chenevix-Trench; Amanda B Spurdle; Penelope M Webb
Journal:  Eur J Cancer       Date:  2006-11-03       Impact factor: 9.162

8.  Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.

Authors:  Hee Seung Kim; Mi-Kyung Kim; Hyun Hoon Chung; Jae Weon Kim; Noh Hyun Park; Yong Sang Song; Soon Beom Kang
Journal:  Gynecol Oncol       Date:  2009-02-08       Impact factor: 5.482

9.  Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.

Authors:  Deolinda Pereira; Joana Assis; Mónica Gomes; Augusto Nogueira; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2016-01-23       Impact factor: 2.953

Review 10.  Role of glutathione in cancer progression and chemoresistance.

Authors:  Nicola Traverso; Roberta Ricciarelli; Mariapaola Nitti; Barbara Marengo; Anna Lisa Furfaro; Maria Adelaide Pronzato; Umberto Maria Marinari; Cinzia Domenicotti
Journal:  Oxid Med Cell Longev       Date:  2013-05-20       Impact factor: 6.543

View more
  1 in total

1.  GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.

Authors:  Tomoko Yoshihama; Koya Fukunaga; Akira Hirasawa; Hiroyuki Nomura; Tomoko Akahane; Fumio Kataoka; Wataru Yamagami; Daisuke Aoki; Taisei Mushiroda
Journal:  Oncotarget       Date:  2018-07-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.